MACROGENICS, INC. Lease, Cost
MACROGENICS, INC. (MGNX) reported Lease, Cost of $6.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-09
- MACROGENICS, INC. lease, cost for the quarter ending 2019-12-31 was $1.41M.
- MACROGENICS, INC. lease, cost for the quarter ending 2019-09-30 was $1.63M.
- MACROGENICS, INC. lease, cost for the quarter ending 2019-06-30 was $1.51M.
- MACROGENICS, INC. lease, cost for the quarter ending 2019-03-31 was $1.34M.
- MACROGENICS, INC. lease, cost for fiscal 2025 was $6.36M, a 3.31% decline from fiscal 2024.
- MACROGENICS, INC. lease, cost for fiscal 2024 was $6.58M, a 14.18% decline from fiscal 2023.
- MACROGENICS, INC. lease, cost for fiscal 2023 was $7.67M, a 28.37% increase from fiscal 2022.
- MACROGENICS, INC. lease, cost for fiscal 2022 was $5.97M, a 3.70% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.36M 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $6.58M 10-K · filed 2026-03-09 | |||
| 2023-12-31 | $7.67M 10-K · filed 2025-03-20 | |||
| 2022-12-31 | $5.97M 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $5.76M 10-K · filed 2023-03-15 | |||
| 2020-12-31 | $5.72M 10-K · filed 2022-02-24 | |||
| 2019-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.04M derived: sum of 2 quarters · filed 2021-02-25 | $4.54M derived: sum of 3 quarters · filed 2021-02-25 | $5.89M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $3.13M derived: sum of 2 quarters · filed 2019-11-06 | $4.47M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $2.85M 10-Q · filed 2019-07-31 | ||
| 2019-03-31 | $1.34M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |